Relmada Therapeutics (RLMD) revenue and earnings history
Relmada Therapeutics's annual figures for 15 fiscal years, as filed with the SEC.
Over 1 years, from fiscal 2012 to fiscal 2013, revenue grew at a compound rate of −35.4% a year.
Revenue and net income, 15 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | — | −$59.1M | −$57.4M | −$45.8M | — | — | $13.9M | — | — | $3.5M | — | 10-K |
| 2024ended Dec 31, 2024 | — |
The latest quarter, insider trades and fund moves: Relmada Therapeutics (RLMD) on OQRO.
Common questions
How fast has Relmada Therapeutics's revenue grown?
From $7.9K in fiscal 2012 to $5.1K in fiscal 2013: a compound annual growth rate of −35.4% over 1 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Has Relmada Therapeutics been profitable?
It reported a net loss in 15 of the years shown (2012, 2013, 2013, 2015, 2016, 2017, 2018, 2019, 2019, 2020, 2021, 2022, 2023, 2024, 2025). The highest net income was −$12K in fiscal 2012.
Does Relmada Therapeutics buy back shares or pay dividends?
None of the 15 annual reports shown tags a share buyback or a dividend payment in the standard US taxonomy.
Where these figures come from
The SEC’s companyfacts data: every figure Relmada Therapeutics tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
